AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
Our Partners
We’re On a Mission
AlloVir is advancing a pipeline of allogeneic, off-the-shelf, virus-specific T cell therapies to prevent or treat life-threatening viral diseases
Partner with Us
We welcome discussions with industry, government and non-profit organizations about potential partnership and licensing opportunities that can facilitate and expedite the delivery of our therapies to patients in need, including:
- Global and regional licensing opportunities across our pipeline, including our investigational SARS-CoV-2 specific VST therapy, ALVR109
- Co-development or co-commercialization partnerships
- Research and development collaborations to explore new indications, new patient populations, or new applications for our VST platform
Partner with us
Ongoing partnerships
Baylor College of Medicine
Our technology platform was developed by world-class scientists at the Baylor College of Medicine’s Center for Cell and Gene Therapy. We continue to collaborate on basic and translational research of novel cell therapies through sponsored research agreements.
To discuss partnering with AlloVir, please submit an inquiry to: bd@allovir.com
